Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents

Patent metadata

Field	Value
Publication number	US-2025387480-A1
Application number	US-202519263165-A
Country	US
Kind code	A1
Filing date	Jul 8, 2025
Priority date	Feb 25, 2019
Publication date	Dec 25, 2025
Grant date	—

Abstract

The disclosure relates to the engineering of collagen-binding modification of anti-inflammatory agents using collagen-binding peptide (CBP) and vWF A3 to achieve targeted therapy for inflammatory diseases. Accordingly, embodiments of the disclosure relate to a composition comprising an anti-inflammatory agent operatively linked to an extracellular matrix (ECM)-affinity peptide. Also disclosed are cytokines and anti-inflammatory agents, such as CD200, linked to a serum protein and/or an ECM-affinity peptide. Further aspects of the disclosure relate to a method for treating an autoimmune or inflammatory condition in a subject comprising administering a composition of the disclosure to the subject.

First claim

1 . A composition comprising a fusion protein comprising an anti-inflammatory agent operatively linked to either i) an extracellular matrix (ECM)-affinity peptide or ii) a serum protein.

2 . The composition of claim 1 , wherein the anti-inflammatory agent comprises a cytokine polypeptide.

3 . The composition of claim 2 , wherein the cytokine polypeptide comprises a polypeptide from IL-4, IL-Ira, IL-5, IL-10, IL-11, IL-23, IL-35, IL-36ra, IL-37, interferon-γ, TGF-β1, TNF receptor I, and TNF receptor II.

4 . The composition of claim 1 , wherein the fusion protein comprises, in order, the ECM-affinity peptide, the serum protein, and the anti-inflammatory agent.

5 . The composition of claim 1 , wherein the ECM-affinity peptide comprises a collagen binding domain.

6 . The composition of claim 5 , wherein the ECM-affinity peptide comprises a collagen binding domain from decorin or von Willebrand factor (VWF).

7 . The composition of claim 1 , wherein the ECM-affinity peptide comprises a collagen binding domain (CBD) from von Willebrand factor (VWF).

8 . The composition of claim 1 , wherein the ECM-affinity peptide comprises a peptide with an amino acid sequence that is at least 85% identical to one of SEQ ID NOS: 3, 4, 5, 47, or 52 or a peptide having an amino acid sequence that is at least 85% identical to a fragment of one of SEQ ID NOS: 3, 4, 5, 47, or 52.

9 . The composition of claim 6 , wherein the ECM-affinity peptide comprises a peptide with an amino acid sequence that is at least 85% identical to one of SEQ ID NOS: 3, 4, 5, 47, or 52 or a peptide having an amino acid sequence that is at least 85% identical to a fragment of one of SEQ ID NOS: 3, 4, 5, 47, or 52.

10 . The composition of claim 1 , wherein the operative linking is selected from covalent linking, crosslinking through a bifunctional linker and linking through a peptide bond.

11 . The composition of claim 1 , wherein the serum protein comprises albumin.

12 . The composition of claim 6 , wherein the serum protein comprises albumin.

13 . The composition of claim 8 , wherein the serum protein comprises albumin.

14 . The composition of claim 1 , wherein the ratio of ECM-affinity peptide to the anti-inflammatory agent is about 1:1 to 5:1.

15 . The composition of claim 11 , wherein the anti-inflammatory agent comprises a cytokine polypeptide.

16 . The composition of claim 11 , wherein the cytokine polypeptide comprises a polypeptide from IL-4, IL-Ira, IL-5, IL-10, IL-11, IL-23, IL-35, IL-36ra, IL-37, interferon-γ, TGF-βI, TNF receptor I, and TNF receptor II.

17 . A composition comprising a fusion protein comprising an anti-inflammatory agent operatively linked to a collagen binding domain and a serum albumin protein.

18 . The composition of claim 17 , wherein the anti-inflammatory agent comprises a cytokine polypeptide.

19 . The composition of claim 18 , wherein the cytokine polypeptide comprises a polypeptide from IL-4, IL-Ira, IL-5, IL-10, IL-11, IL-23, IL-35, IL-36ra, IL-37, interferon-γ, TGF-βI, TNF receptor I, and TNF receptor II.

20 . The composition of claim 17 , wherein the operative linking is selected from covalent linking, crosslinking through a bifunctional linker and linking through a peptide bond.

Assignees

• Univ Chicago

Inventors

• Hubbell Jeffrey A
• Katsumata Kiyomitsu
• Ishihara Ako
• Ishihara Jun
• Mansurov Aslan

Classifications

• A61K38/215

  IFN-beta · CPC title

• A61K38/2073

  IL-11 · CPC title

• A61K38/2066

  IL-10 · CPC title

• A61K38/2033

  IL-5 · CPC title

• A61K38/2026

  IL-4 · CPC title